Sponsors (3)
The bill expands and reduces the cost barrier to naloxone for veterans—improving overdose prevention—but shifts financial and operational responsibility to the VA and may produce uneven access without dedicated funding and clear implementation guidance.
Veterans can obtain naloxone from the VA without a prescription, increasing immediate access and likely reducing fatal opioid overdoses among veterans.
Veterans face lower out-of-pocket costs and fewer administrative barriers to obtaining opioid antagonists from the VA because a copayment-related provision was removed.
The provision does not specify funding, so the VA may need to absorb the cost of supplying naloxone, potentially diverting resources from other VA services and straining hospitals/health-systems.
The law lacks implementation details (distribution channels, training, recordkeeping), risking inconsistent availability of naloxone across VA facilities and uneven access for veterans until guidance is issued.
Based on analysis of 2 sections of legislative text.
Requires VA to provide an opioid antagonist to veterans without a prescription and removes a copayment-related provision from VA drug benefits law.
Requires the Department of Veterans Affairs to provide an opioid antagonist (e.g., naloxone) to a veteran without requiring a prescription, and removes a copayment-related provision from the VA pharmaceutical benefits rules. The bill updates the veterans benefits code to add the new authority but does not specify funding or an effective date.
Introduced November 10, 2025 by Herbert C. Conaway · Last progress November 10, 2025